Pharming Group N.V.
PHAR
$13.40
-$0.879-6.16%
NASDAQ
06/30/2025 | 12/31/2024 | 06/30/2024 | 03/31/2024 | ||
---|---|---|---|---|---|
Revenue | -- | -- | 34.57% | 28.21% | |
Total Other Revenue | -- | -- | -- | -- | |
Total Revenue | -- | -- | 34.57% | 28.21% | |
Cost of Revenue | -- | -- | 72.97% | 77.02% | |
Gross Profit | -- | -- | 30.81% | 23.81% | |
SG&A Expenses | -- | -- | 19.56% | 31.44% | |
Depreciation & Amortization | -- | -- | -- | -- | |
Other Operating Expenses | -- | -- | 69.82% | 78.71% | |
Total Operating Expenses | -- | -- | 26.20% | 37.92% | |
Operating Income | -- | -- | 17.31% | -141.99% | |
Income Before Tax | -- | -- | 30.19% | -102.78% | |
Income Tax Expenses | -- | -- | 63.14% | 69.92% | |
Earnings from Continuing Operations | -- | -- | 18.84% | -440.48% | |
Earnings from Discontinued Operations | -- | -- | -- | -- | |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
Minority Interest in Earnings | -- | -- | -- | -- | |
Net Income | -- | -- | 18.84% | -440.48% | |
EBIT | -- | -- | 17.31% | -141.99% | |
EBITDA | -- | -- | 44.20% | -405.43% | |
EPS Basic | -- | -- | 23.31% | -435.48% | |
Normalized Basic EPS | -- | -- | 60.72% | -80.66% | |
EPS Diluted | -- | -- | 27.40% | -108.54% | |
Normalized Diluted EPS | -- | -- | 60.72% | -70.31% | |
Average Basic Shares Outstanding | -- | -- | 4.93% | 6.49% | |
Average Diluted Shares Outstanding | -- | -- | 2.94% | -0.43% | |
Dividend Per Share | -- | -- | -- | -- | |
Payout Ratio | -- | -- | -- | -- |